Skip to content
type1.science

Medtronic Guardian 4

Medtronic

What it is

A seven-day CGM with a separate rechargeable transmitter, used with MiniMed 780G. Routine calibration is unnecessary, but US manual-mode dosing still requires a meter. Australian standalone Guardian-app use ended under updated approved-use guidance from September 2026. Sensor accuracy and whole-system outcomes are different evidence questions.

Editorial review: .

Most recent recorded citation date: 2026-07-28. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

780G access; local checks neededRegulator-approvedcgmOfficial site ↗

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
Benefit or performance
Accuracy: FDA Table 17 reports MARD 10.6% in 153 adults/20,612 arm–YSI pairs and 11.6% in 107 ages 7–17/7, 702 pairs. This was retrospective zero-calibration processing of equivalent Guardian Sensor 3 hardware; separate-device studies do not establish a reliable accuracy ranking.[1]
Important harms and treatment burden
Read the safety discussion and original sources. A missing summary does not establish safety.
Approval and country access
US and Canadian manufacturer pathways and Australian 780G use are documented. Australian standalone use has ended. UK/EU listings provide regional context; new-customer stock and local funding are not confirmed.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Read the full discussion and original sources for follow-up duration and study limitations.

This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

Editorial score: calculation and evidence

A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.

Score limitations. Numerical scores are retained editorial judgments. They are not validated probabilities or a cross-trial accuracy ranking. Country listings do not establish every local indication, current stock or reimbursement.

Default calculation: 70 × 20 + 62 × 15 + 30 × 15 + 60 × 10 + 90 × 10 + 80 × 10 + 45 × 10 + 0 × 5 + 55 × 5 = 5805; divide by total weight 100. Unrounded weighted result: 58.05.

Accuracy70

FDA Table 17 reports MARD 10.6% in 153 adults/20,612 arm–YSI pairs and 11.6% in 107 ages 7–17/7, 702 pairs. This was retrospective zero-calibration processing of equivalent Guardian Sensor 3 hardware; separate-device studies do not establish a reliable accuracy ranking.[1]

Low lag62

The sensor measures glucose in interstitial fluid. The cited label does not establish a fixed 10–15-minute delay or demonstrate that this device removes lag; this score remains editorial.[2]

Interoperability30

The current US manufacturer comparison lists Guardian 4 with 780G. Compatible hardware is specified by the regional system label; the listing does not certify every other or open-source integration.[6]

Sensor lifespan60

The US sensor label allows up to seven days of use. This is a maximum labeled wear period, not a promise every sensor will last seven days.[2]

No calibration90

The US system does not need routine calibration, but manual-mode treatment decisions require meter readings. SmartGuard also has meter-check exceptions; calibration-free does not mean a meter can be discarded.[1]

Alerts & prediction80

Guardian 4 supplies glucose information to the 780G system. The integrated-system study reports SmartGuard use and outcomes; it does not isolate the benefit of the sensor’s alerts from the pump algorithm.[3]

Form factor45

The manufacturer comparison lists a separate sensor, reusable transmitter and reusable serter. This adds reusable components compared with its all-in-one sensor configurations.[6]

Ketone sensing0

The labeled measurement is interstitial glucose, not ketones.[2]

Access & cost55

The US pharmacy copay programme is limited to eligible commercial-insurance beneficiaries, applies benefit caps and excludes Medicare and other government-funded plans. It is not evidence that Guardian 4 is widely reimbursed in every listed region.[7]

Editor’s take

The practical decision is which locally supported sensor works with your 780G and fits your insertion, charging and coverage needs. Guardian 4’s separate transmitter and seven-day maximum wear are clear trade-offs. Its accuracy cannot fairly be ranked against another device by comparing headline MARDs from different trials; the whole 780G system also matters.

The full picture

Guardian 4 is a glucose sensor with a separate reusable, rechargeable transmitter. The current US product comparison lists it as one of the MiniMed 780G pump’s sensor options, alongside Simplera Sync and Instinct. Standalone Simplera is a different configuration for InPen. These product listings do not establish that every option is supplied in every country.65

US indication and meter use. The US Guardian 4 sensor label specifies ages 7 and older, arm insertion and up to seven days of use. It describes an adjunctive sensor and expressly requires meter values for treatment decisions when the AID system is in manual mode. Routine calibration is not required; this does not remove SmartGuard meter-check requirements or the need to check readings that disagree with symptoms. Local system instructions govern use.21

Accuracy: identify the dataset. FDA’s 2023 summary reports arm–YSI MARD of 10.6% in 153 adults with 20,612 pairs and 11.6% in 107 participants aged 7–17 with 7,702 pairs. The study used equivalent Guardian Sensor 3 hardware with raw signals processed retrospectively by the zero-calibration algorithm. These are analysis-table denominators. The FDA report’s methods also describe 122 adult completers; that conflicts with its 153-adult accuracy table and is not reconciled here. They should not be compared with an unrelated device’s headline MARD as if the devices had been tested together.1

What the published system study shows. Cordero and colleagues reported 109 children/adolescents and 67 adults in a three-month continued-access phase, plus real-world uploads from 10,204 younger and 26,099 older users. The study describes 780G-with-Guardian 4 performance, not an isolated sensor effect or randomized sensor comparison. Its frequently quoted 10.8% accuracy figure refers to an earlier 2021 conference abstract, not its own accuracy dataset. The study was funded by Medtronic.3

Wear and water. The labeled maximum is seven days and current US support specifies a two-hour warm-up. The transmitter is recharged and reused with new sensors. When correctly connected, the transmitter and sensor form a water-resistant seal rated to 2.4 metres for up to 30 minutes; the disconnected transmitter must not be exposed to liquid. This rating is not a statement about the pump’s water limits.245

Safety. The US sensor guide warns against use with hydroxyurea; acetaminophen/paracetamol may falsely raise readings. It also warns against use during pregnancy or critical illness because performance has not been studied in those groups, and addresses insertion-site infection and strong magnetic fields. It measures glucose, not ketones.2

Australian access changed. A 28 July 2026 NDSS notice states that standalone Guardian System 4 transmitter code 985 ceased NDSS availability from 1 September 2026. It also states that updated approved use restricts Guardian Sensor 4 to 780G with Guardian Link 4 and ends standalone Guardian-app use. Medtronic’s Australian product page still advertises standalone use, so that page should not be treated as current approval or access evidence. NDSS describes transition support for affected eligible users.89

Other access. Current US commercial-insurance copay terms and a Canadian manufacturer pathway are available, with eligibility and benefit limits. UK support and Czech product pages provide regional context, but this review did not confirm current new-customer supply or funding throughout the UK or EU. Nor does the present choice of US 780G sensors prove Guardian 4 is being discontinued everywhere or that users are progressively switching to one named successor.71011126

Recall and advisory scope. FDA recall Z-1005-2024 covers specified Guardian 4 lots with a glucose-oxidase layer problem that could affect readings or cause sensor failure; consult its exact affected-lot list and replacement instructions. A separate 2026 MiniMed 780G correction concerns insulin delivery when pump height changes relative to the infusion site, including a warning not to place the pump more than 35.5 cm above the site. That is a pump-use correction, not another Guardian 4 sensor-lot recall. These notices do not establish that every Guardian 4 sensor is defective.1314

Sources

  1. [1]
    FDA MiniMed 780G with Guardian 4 — summary of safety and effectiveness · Regulatory decision · 2023-04-21 — April 2023 approval. G190047 accuracy study, pp 33–39/Table 17: retrospective zero-calibration algorithm on equivalent Guardian Sensor 3 hardware; 153 adults/20,612 arm–YSI pairs, 107 ages 7–17/7,702 pairs. Separate from Cordero’s integrated-system outcomes.
  2. [2]
    FDA Guardian 4 sensor labeling — P250012 · Regulatory decision — Combined file includes Simplera Sync first; Guardian 4 section printed pp 5–7 (physical PDF pp 53–55) specifies age 7+, arm, up to 7 days, adjunctive/manual-mode meter instructions and safety warnings. Do not apply Sync-specific instructions to Guardian 4.
  3. [3]
    Glycemic Outcomes During Early Use of the MiniMed 780G Advanced Hybrid Closed-Loop System with Guardian 4 Sensor · Peer-reviewed study — Full 2023 paper: continued-access 109 children/adolescents and 67 adults; real-world 10,204 younger plus 26,099 older users. Medtronic funded. The 10.8%/18,423-pair accuracy figure is a citation to a 2021 conference abstract, not this paper’s own accuracy dataset.
  4. [4]
    Guardian 4 — current US sensor support · Manufacturer — Two-hour warm-up, insertion/taping and sensor updating instructions. Read 17 September 2026.
  5. [5]
    Guardian 4 transmitter user guide — US · Manufacturer — MAPS 531429-014. Rechargeable transmitter and charger; bathing/swimming requires connected sensor/transmitter seal, 2.4 m up to 30 min. Do not wet disconnected transmitter. Read 17 September 2026.
  6. [6]
    Medtronic continuous glucose monitors — US comparison · Manufacturer — Separates Simplera/InPen from Simplera Sync/780G and Guardian 4/780G. Current product configuration and wear information; no clinical superiority inference. Read 17 September 2026.
  7. [7]
    CGM Pharmacy Copay Program — US · Manufacturer — Commercial-insurance/pharmacy-benefit restrictions, benefit caps and government-plan exclusions. Current 780G safety text and sensor choices are displayed. Not evidence of universal reimbursement. Read 17 September 2026.
  8. [8]
    Guardian System 4 transmitter to be discontinued · Public health programme · 2026-07-28 — NDSS code 985 unavailable from 1 September 2026; updated approved use restricts Guardian Sensor 4 to 780G with Guardian Link 4, ending standalone Guardian-app use. Transition support described.
  9. [9]
    Guardian 4 system — Australian manufacturer page · Manufacturer — Still advertises standalone use when read 17 September 2026. Conflicts with newer dated NDSS restriction; not used as evidence of current standalone approval or supply.
  10. [10]
    CGM coverage — MiniMed Canada · Manufacturer — Current manufacturer pathway for 780G with Guardian 4 and links to provincial criteria. Provincial rules and current fulfilment were not individually verified. Read 17 September 2026.
  11. [11]
    Medtronic Diabetes UK help centre · Manufacturer — Lists Guardian 4 among support products. A support listing is not proof of current new-customer supply or funding. Read 17 September 2026.
  12. [12]
    Guardian 4 system — Czech manufacturer page · Manufacturer — Current page advertises Guardian 4 but carries 2021-era material and both standalone and pump text. Supports regional product context; current stock and country-specific approved configuration remain unconfirmed. Read 17 September 2026.
  13. [13]
    FDA recall Z-1005-2024 — specified Guardian 4 lots · Regulatory decision · 2024-02-07 — Initiated 15 November 2023; posted 7 February 2024. Listed lots may have an out-of-specification glucose-oxidase layer, causing inaccurate readings or failure. Open/classified when read 17 September 2026.
  14. [14]
    FDA recall Z-1741-2026 — MiniMed 780G pump positioning correction · Regulatory decision · 2026-04-02 — Initiated 13 February 2026, posted 2 April 2026. Pump elevation relative to infusion site can alter insulin delivery; guide correction includes keeping pump no more than 35.5 cm above site. Pump issue, not a new Guardian 4 sensor-lot recall.